La mutation KIT dans le facteur de liaison du coeur (FBC) AML (t(8;21) / inv(16)) est enrichie (~25-30%) a...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-KIT-MUTATION-AML |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-KIT |
|---|---|
| Variante | activating mutation (exon 17 D816V / N822K most common; ~25-30% of core-binding-factor AML) |
| Maladie | DIS-AML |
| Niveau ESCAT | IIA |
| Combinaisons recommandées | standard 7+3 + HiDAC consolidation (CBF-AML backbone), dasatinib + 7+3 + HiDAC (CALGB-10801 trial / off-label intensification for CBF-AML KIT-mut), avapritinib (D816V-AML, basket trial) |
| Contre-indiqué en monothérapie | imatinib (D816V-resistant; not active in CBF-AML in clinical trials) |
| Résumé des faits | KIT mutation in core-binding-factor (CBF) AML (t(8;21) / inv(16)) is enriched (~25-30%) and confers worse OS vs CBF-AML wild-type. Dasatinib + 7+3 + HiDAC consolidation (CALGB-10801, Marcucci Blood 2020 — CBF-AML setting) is being studied; not standard. Avapritinib has activity in D816V-mutant AML basket cohorts but no AML approval. ELN 2022 considers KIT mutation in CBF-AML as intermediate/adverse-risk modifier within the favorable CBF subset. |
Notes
ESCAT IIA. OncoKB Level 3A. KIT testing should be performed on every CBF-AML at diagnosis; result modifies prognosis and trial eligibility but does not yet change standard-of-care chemo backbone outside trials. Trial-source gap: SRC-CALGB-10801 not yet ingested.
Utilisé par
No reverse references found in the YAML corpus.